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Tumor-infiltrating myeloid cells contribute to the development of the immunosuppressive 
tumor microenvironment. Myeloid cell expression of arginase 1 (Arg-1) promotes a protumor 
phenotype by inhibiting T cell function and depleting extracellular L-arginine, but the mechanism 
underlying this expression, especially in breast cancer, is poorly understood. In breast cancer 
clinical samples and in our mouse models, we identified tumor derived GM-CSF as the primary 
regulator of myeloid cell Arg-1 expression and local immune suppression through a gene 
knockout screen of breast tumor cell-produced factors. The induction of myeloid cell Arg-1 
required GM-CSF and a low pH environment. GM-CSF signaling through STAT3, p38 MAPK, and 
acid signaling through cAMP were required to activate myeloid cell Arg-1 expression in a STAT6 
independent manner. Importantly, breast tumor cell-derived GM-CSF promoted tumor 
progression by inhibiting host anti-tumor immunity, driving a significant accumulation of Arg-1 
expressing myeloid cells compared to lung and melanoma tumors with minimal GM-CSF 
expression. Blockade of tumoral GM-CSF enhanced the efficacy of tumor-specific adoptive T-cell 
therapy and immune checkpoint blockade. Taken together, breast tumor cell-derived GM-CSF 
contributes to the development of the immunosuppressive breast cancer microenvironment by 

















Immunotherapy is heralded for its promise in cancer (1). Emerging clinical evidence suggests 
that the immunosuppressive tumor microenvironment (TME) represents a major obstacle for 
treatment success against several tumor types, including breast cancer (1-3). Higher rates of 
tumor-infiltrating lymphocytes (TILs) are associated with an increase in durable response and 
survival (1, 4-6) and have shown promise as indicators of positive response to immune checkpoint 
blockade (ICB) treatment (1, 7). However, accumulation of inhibitory cells, such as myeloid-
derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), as well as 
metabolic constraints inherent to the TME, are important contributors to T cell dysfunction (2, 3, 
8, 9). Thus far, no robust predictive biomarkers for ICB have been established in breast cancer 
(1). 
With tumor progression, a supportive and immunosuppressive TME is developed comprising 
immune cells, cancer-associated fibroblasts (CAFs), endothelial cells, and stromal cells, all 
embedded within an extracellular matrix (ECM) (3, 10). Heterogeneous populations of tumor-
infiltrating myeloid cells (TIMs) are the most abundant immune-related cells in the TME and 
include monocytes, tumor-associated neutrophils, tumor-associated dendritic cells (DCs), MDSCs, 
and TAMs (2, 8, 9). In the TME, TIMs exhibit a diverse range of functional phenotypes from 
antitumor to protumor (2, 8, 9). TAMs, for example, are often broadly divided into one of two 
categories: anti-tumorigenic or “M1” TAMs, which express high levels of tumor necrosis factor 
(TNF), inducible nitric oxide synthase (iNOS, or NOS2), and MHC class II molecules; and pro-
tumorigenic or “M2” TAMs, which express high levels of arginase 1 (Arg-1), IL-10, and CD206 (2). 
In many cancer types, including breast cancer, TIMs often exhibit a protumor phenotype in the 
TME, where they promote tumor growth and metastasis and are associated with poor prognosis 
in cancer patients (2, 11-13). Indeed, protumor TIMs, especially M2 TAM subsets, can directly 
inhibit cytotoxic T lymphocyte (CTL) function through at least three distinct mechanisms, 
including direct cell-cell contact inhibition through checkpoint inhibitory molecules such as PD-
L1, production of inhibitory cytokines like IL-10 and TGF-, and modulation of the metabolic 




Breast cancer tissue is usually infiltrated with a high number of myeloid cells (2, 13), and the 
presence of abundant CD68+ myeloid cells with low CD8+ CTL infiltration is negatively correlated 
with patient survival (13). Breast tumor cell-derived factors, especially members of the colony-
stimulating factor (CSF) superfamily such as macrophage (M)-CSF (or CSF1), granulocyte (G)-CSF 
(or CSF3), and GM-CSF (or CSF2), can directly influence myeloid cell populations, regulating their 
recruitment, proliferation, and function (2, 9, 11, 12). GM-CSF is expressed by nearly 60% of 
breast cancer patient tumors (14), and has been shown to activate plasmacytoid predendritic 
cells (pDC) to promote a regulatory Th2 response and to induce immunosuppressive myeloid cells 
(14-17).  
Arg-1 is a well characterized marker of immunosuppressive myeloid cells, and myeloid cell 
arginine metabolism regulates both innate and adaptive immunity (18). Compared to NOS2 or 
Arg-2, Arg-1 expression in macrophages plays a larger role in regulating extracellular L-arginine 
levels (19). TIM-derived Arg-1 can directly suppress T cell function by depleting L-arginine, 
inhibiting T cell receptor expression and responses (2, 3, 9, 20). Inhibition of Arg-1 reduces the 
growth of tumors only in immunocompetent mice (20), and macrophage-specific deletion of Arg1 
in mice improved responses to adoptive cell transfer therapy (21). However, in breast cancer, the 
role and mechanism of Arg-1 expression is not fully understood. 
In this study, we found increased numbers of Arg-1+ myeloid cells in breast cancer preclinical 
models and in breast cancer patient tumors compared to lung cancer and melanoma tumors. 
Using CRISPR/Cas9-mediated gene knockout screening in breast cancer cells, we identified GM-
CSF as a critical cytokine regulating myeloid cell Arg-1 expression in the breast cancer TME. We 
show that GM-CSF promotes primary and metastatic tumor growth through these effects on 
myeloid cell Arg-1 expression. GM-CSF and the acidic TME were required for TIM Arg-1 
expression through JAK/STAT3 and cAMP pathways, respectively. Finally, disruption of tumoral 
GM-CSF reversed resistance to T-cell therapy and immune checkpoint inhibitors. Our data 
suggest that breast tumor cell-derived GM-CSF contributes to the development of the 







Arg-1 expressing myeloid cells accumulate in the breast tumor microenvironment 
In breast cancer patients, an abundance of myeloid cells and low T cell infiltration in the tumor 
tissue is associated with poor outcomes (13).  To evaluate myeloid cell and T cell dynamics in the 
breast cancer TME, we performed FACS analysis of immune populations in an orthotopic model 
of murine ER+ luminal B breast cancer, PyMT-BO1-GFP-Luc (BO1) in syngeneic C57BL/6 mice (22), 
at several time points during tumor progression. We found that the percentage of CD4+ and CD8+ 
T cells among total tumor-infiltrating leukocytes decreased over time, while CD11b+ myeloid cells 
increased. Moreover, the majority of infiltrated TAMs were of the CD206 expressing, pro-
tumorigenic “M2” phenotype (Figure 1A and 1B). The murine ER-PR-Her2- “triple-negative” 4T1 
breast tumor cell line has also been shown to recruit high levels of M2 polarized macrophages 
and exhibits reduced levels of infiltrating T cells in syngeneic BALB/c mice (23). 
Arg-1 is an established biomarker for pro-tumor “M2” polarized macrophages (2). To track 
Arg-1 expressing macrophages during tumor development in vivo, we established orthotopic BO1 
tumors in Arg-1 reporter mice (YARG), in which an enhanced yellow fluorescent protein (EYFP) is 
expressed under the control of the Arg-1 promoter without disruption of normal Arg-1 expression 
(24). We found that the majority of Arg-1 expressing cells in the breast TME were myeloid cells, 
and that the tumor-infiltrating CD45+ CD11b+ myeloid cell population consistently represented 
about half of the cells expressing Arg-1 (Figure 1C and 1D). Importantly, Arg-1+ cells were found 
in all myeloid cell subpopulations studied (Figure 1E). Further, we found that Arg-1 expressing 
TIMs were mostly CCR2+, pointing toward a bone marrow origin (25, 26) (Figure 1F). However, 
we did not observe Arg-1 induction in the spleen or in bone marrow-resident myeloid cells from 
tumor-bearing mice, suggesting that Arg-1 induction in tumor-infiltrating myeloid cells primarily 
occurred within the breast TME (Figure S1).  
Comparing BO1 breast tumors with subcutaneous B16F10 melanoma or LLC lung tumor tissue 
in C57BL/6 mice, we found that the number of Arg-1+ myeloid cells was exceptionally high in 
murine breast tumor tissue (Figure 1G). IHC staining confirmed high numbers of Arg-1 expressing 
cells in the murine BO1 and 4T1 breast tumor tissues (Figure S2). By multi-color 
immunofluorescence, we found that most Arg-1 expressing myeloid cells were located in the 
tumor core (Figure 1H). 
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We next evaluated breast cancer, melanoma, and lung cancer tissue from human patients for 
myeloid cell Arg-1 expression by immunofluorescence staining. All cancer types exhibited 
infiltrating CD68+ myeloid cells, but breast cancer tissue had a significantly higher number of 
CD68+ infiltrating cells per tissue area (Figure 2A).  Moreover, less than 10% of CD68+ cells in 
melanoma and lung cancers expressed Arg-1, whereas over 45% of CD68+ cells were Arg-1+ in 
breast cancer tissue (Figure 2B). Evaluation of myeloid subsets in the most common breast cancer 
subtypes (ER+, Her2+, and triple negative breast cancer- TNBC) showed higher levels of infiltrating 
CD68+ myeloid cells compared to normal breast tissue (Figure 2C). In contrast to TNBC, the ER+ 
and Her2+ breast cancer subsets had similar ratios of CD68+ cells expressing Arg-1 (Figure 2D). 
When comparing the Arg-1+ CD68+ cell numbers based on tumor stage, we found that the number 
of Arg-1+ CD68+ myeloid cells increased in later stage cancer (Figure 2E).  
These data demonstrate that Arg-1 expressing myeloid cells accumulate at high levels in the 
breast TME in the three major breast cancer subtypes. Our data also suggest that the breast 
cancer TME has unique properties that drive tumor-infiltrating myeloid cell Arg-1 expression 
compared to lung or melanoma tumors.  
Tumor cell-produced GM-CSF is necessary to induce myeloid cell Arg-1 expression 
To test if tumor cells can directly induce myeloid cell Arg-1 expression, we treated bone 
marrow macrophages (BMMs) with conditioned media (CM) collected from tumor cells. We used 
BMM because the majority of tumor infiltrating myeloid cells expressed high levels of CCR2, 
suggestive of an origin in the bone marrow; additionally, they represent an abundant and reliable 
source of myeloid cells for mechanistic biochemical studies. We found that both BO1 and 4T1 
breast tumor cell-derived CM strongly induced Arg-1 expression in BMMs, while CM collected 
from Lewis lung carcinoma (LLC) or B16F10 melanoma cells did not (Figure 3A). Tumor cell-
derived CM had no direct inhibitory effect on T cell proliferation (Figure 3B), prompting us to 
evaluate the effect of CM from Arg-1+ macrophages. BMMs were exposed to tumor cell-derived 
CM for 24 hours and FACS sorted into Arg-1+ and Arg-1- CD11b+ populations; CM from these 
sorted populations was then harvested and added to the T cell proliferation assay. We found that 
only conditioned media from Arg-1+ myeloid cells had an inhibitory effect on the proliferation of 
activated T cells (Figure 3B, sFigure 3). 
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To identify candidate tumor-derived secreted factors that could promote pro-tumor myeloid 
cell phenotypes in the TME, we performed gene expression analysis of FACS sorted tumor cells 
(GFP+) and tumor-associated macrophages (CD206+) from BO1 mammary fat pad (MFP) tumors. 
We found that breast tumor cells express many cytokines and growth factor genes and that TAMs 
from the breast cancer microenvironment express their reciprocal receptors (Figure 3C). We 
performed a knockout screen of candidate secreted factors in BO1 and 4T1 breast cancer cells 
using the CRISPR/Cas9 lentiviral vector system. We validated targeted gene knockout and 
evaluated tumor cell CM from these knockout lines for the ability to induce BMM Arg-1 
expression, identifying GM-CSF as a prime candidate (Figure 3D, 3E, sFigure 4). We confirmed 
that GM-CSF is present in the CM from WT BO1 and 4T1 cell lines, but absent in CM from 
knockout cell lines, as measured by ELISA. Interestingly, neither B16F10 melanoma cells nor LLC 
lung cancer cells exhibited detectable GM-CSF in their CM (Figure 3F). 
Consistent with knockout studies, pharmacologic blockade of the GM-CSF present in breast 
cancer cell CM using neutralizing antibodies resulted in decreased Arg-1 mRNA expression in 
BMMs; likewise, exogenous GM-CSF added to conditioned media from CSF2 knockout breast 
cancer cells rescued Arg-1 mRNA expression in BMMs (Figure 3G, 3H). We further confirmed the 
effect of GM-CSF depletion or rescue on Arg-1 expression by FACS using BMMs from YARG mice 
(Figure 3I).  
To evaluate whether GM-CSF can regulate Arg-1 expression in vivo, we injected BO1-WT or 
BO1-CSF2 knockout breast tumor cells into MFP tissue of YARG mice and evaluated Arg-1 
expressing myeloid cells by FACS. We found a significantly lower number of Arg-1 expressing 
myeloid cells in BO1-CSF2 knockout tumors (Figure 3J). 
To evaluate the role of GM-CSF in myeloid cell Arg-1 expression in other tumor types, we 
directly injected GM-CSF into established B16F10 tumors and found that the number of Arg-1 
expressing myeloid cells was significantly increased 24 h after GM-CSF injection (sFigure 5). 
To further confirm these results, B16 melanoma and LLC lung cancer cells were engineered to 
overexpress GM-CSF. Conditioned media from GM-CSF expressing B16 and LLC cells induced Arg-
1 expression from BMMs. In vivo, enforced GM-CSF expression yielded cell line-derived tumors 
with significantly more Arg-1 expressing tumor infiltrating myeloid cells (sFigure 6). 
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Together, these results demonstrate that tumor cell-produced GM-CSF is necessary to induce 
myeloid cell Arg-1 expression.  
GM-CSF and lactic acid synergistically induce myeloid cell Arg-1 expression 
GM-CSF can regulate Arg-1 expression in BMMs, but the mechanism is not clear (27). When 
BMMs were treated with GM-CSF alone in naive media, the induced Arg-1 mRNA level was 
surprisingly low compared to the response observed from treatment with BO1 CM (Figure 4A). A 
similar experiment with YARG BMMs demonstrated minimal Arg-1 reporter gene expression after 
GM-CSF alone treatment (Figure 4B). By contrast, the addition of GM-CSF to B16F10 or LLC CM, 
neither of which is sufficient to induce Arg-1, induced Arg-1 mRNA in BMMs to a level comparable 
to BO1 CM (Figure 4C). These data indicate that GM-CSF requires a tumor-derived secreted co-
factor to induce myeloid cell Arg-1 expression. 
Our top candidate for such a co-factor was lactic acid (LA), a common component of the TME 
in multiple cancer types (28) and previously shown to upregulate macrophage Arg-1 expression 
(29). LA dissociates into lactate and free hydrogen ions, actively acidifying the TME, and the anion 
lactate can be measured as a surrogate of tumor cell LA production. Conditioned media from 
BO1, B16F10, and LLC tumor cells had similar concentrations of lactate (10-15 mM) (Figure 4D). 
As with GM-CSF alone in cell culture media, we found that LA alone induced Arg-1 mRNA 
expression in BMMs without significant upregulation at the protein level. Testing multiple 
combinations of GM-CSF and LA at various concentrations, we found that they synergized to 
generate high-level Arg-1 mRNA expression from BMMs in a dose-dependent manner (Figure 4E). 
We confirmed induction of protein expression using this combination both by FACS of BMMs 
from YARG reporter mice and by western blot (Figure 4F and 4G).  
Lactate dehydrogenase A (LDHA), lactate dehydrogenase B (LDHB), and monocarboxylate 
transporter 1 (MCT1) are important for LA production in tumor cells (28). We genetically knocked 
out these genes in BO1 cells to quantify their lactate production and the media pH and found 
that Ldha knockout cells had decreased lactate production and increased media pH (Figure 4H, 
I). Compared to CM from WT cancer cells, CM from Ldha knockout cells resulted in diminished 
Arg-1 induction in BMMs (Figure 4J, 4K).  
Next, we asked whether the molecule lactate, independent of H+, could work with GM-CSF to 
induce myeloid cell Arg-1 expression. Surprisingly, the combination of sodium lactate and GM-
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CSF did not induce Arg-1 expression in BMMs (Figure S7), suggesting that acidified culture 
conditions may play a role in Arg-1 induction. We tested GM-CSF addition to media across a range 
of pH values from 6 to 7.4 for Arg-1 induction. We found that GM-CSF only induced myeloid cell 
Arg-1 expression in acidified media (Figure 4L), and that neutralization of acidic tumor 
conditioned media with sodium bicarbonate (NaHCO3) could block Arg-1 induction (Figure 4M). 
Together, these data indicate that breast tumor-derived GM-CSF is necessary, but not 
sufficient, to induce myeloid cell Arg-1 expression. LA acidification may be functioning as a co-
factor that synergistically induces myeloid cell Arg-1 expression along with GM-CSF. 
Tumor-derived GM-CSF drives Arg-1 expression through non-canonical signaling pathways 
STAT6 signaling is required for macrophage Arg-1 expression induced by IL-4 (12). To test the 
role of STAT6 signaling in breast tumor-induced macrophage Arg-1 expression, we treated BMMs 
from WT YARG mice or Stat6-/- YARG mice with either IL-4 or BO1 CM and detected reporter gene 
EYFP expression by FACS. We found that IL-4 induced Arg-1 expression in WT BMMs, but not in 
Stat6-/- BMMs, while BO1 CM induced Arg-1 expression in both WT and Stat6-/- BMMs (Figure 5A, 
5B). We obtained the same results by qPCR for Arg-1 expression in a parallel experiment (Figure 
5C). In vivo, we found that BO1 orthotopic MFP tumors induced Arg-1 expression by TIMs in both 
WT and Stat6-/- mice (Figure 5D-F). These data suggest that STAT6 signaling is dispensable in 
breast tumor-induced myeloid cell Arg-1 expression. 
Classical GM-CSF signaling proceeds through JAK2/STAT5; however, studies have shown that 
GM-CSF can also activate STAT3, p38 MAPK, MEK, and ERK1/2 signaling pathways (30-32). To 
evaluate the downstream signaling pathways essential to breast tumor-induced Arg-1 expression 
in myeloid cells, we pre-treated BMMs from YARG mice with inhibitors of JAK1/2, STAT3, STAT5, 
p38, MEK, or ERK1/2, then added BO1 CM for 24 hours and analyzed Arg-1 expression by FACS. 
We found that the clinical JAK1/2 inhibitor, ruxolitinib, completely blocked BO1 CM induced Arg-
1 expression; a JAK2 downstream STAT5 inhibitor, meanwhile, had no effect. Both STAT3 and p38 
inhibition reduced BO1 CM-induced Arg-1 expression in a dose-dependent manner. The clinically 
used MEK inhibitor, trabectedin, partially inhibited Arg-1 expression, while ERK1/2 inhibition had 
no effect (Figure 5G-I, sFigure 8). 
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These results suggest that tumor-derived GM-CSF drives breast tumor cell-induced myeloid 
cell Arg-1 expression through non-canonical JAK/STAT3 and p38 MAPK signaling pathways.  
Tumor-derived GM-CSF requires cAMP signaling to drive Arg-1 expression 
Cells can respond to changes in environmental pH through pH sensing G protein-coupled 
receptors (GPCRs) (33). GPCR downstream signaling proceeds through the G alpha subunit, which 
negatively or positively regulates adenylyl cyclase (AC) activity through inhibitory G protein (Gi) 
or stimulatory G protein (Gs), respectively (34, 35) (Figure 6A). We first used the Gi inhibitor 
pertussis toxin (PTX) to pre-treat BMMs from YARG mice for 1 hour, then added breast tumor 
CM for a further 24 hours before analyzing Arg-1 expression by FACS. We found that PTX dose-
dependently enhanced Arg-1 expression (Figure 6B). Forskolin, an AC activator, similarly 
enhanced breast tumor CM-induced BMM Arg-1 expression (Figure 6C). When combined with 
GM-CSF, forskolin was sufficient to induce Arg-1 expression in BMMs (Figure 6D), suggesting that 
acidified tumor CM or LA may signal through the cAMP pathway to induce Arg-1 expression in 
myeloid cells. 
AC activation increases intracellular cyclic AMP (cAMP) concentration and regulates many 
cellular functions through cAMP response element-binding protein (CREB) (35). To test the 
necessity of cAMP to promote Arg-1 expression, we pre-treated BMMs with either MDL-12, an 
AC inhibitor, or KG-501, an inhibitor of CREB binding, then added breast tumor CM or GM-CSF in 
combination with LA to the BMMs. In both conditions, we found a dose-dependent inhibition of 
Arg-1 expression (Figure 6E, 6F).  
Taken together, these results suggest that tumor cell-derived GM-CSF-induced myeloid cell 
Arg-1 expression requires both cAMP signaling and the JAK/STAT3 signaling pathways (Figure 6G 
proposed model). 
Breast tumor-derived GM-CSF promotes tumor growth through the modulation of host 
immune cells 
To evaluate the functional role of tumor-derived GM-CSF on breast tumor growth in vivo, we 
inoculated 4T1-WT or 4T1-CSF2KO (GM-CSF knockout) cells into the MFP tissue of BALB/c mice 
and measured tumor growth by caliper. We found that GM-CSF knockout tumor cells had 
significantly decreased tumor growth (Figure 7A) in immunocompetent mice. We performed the 
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same experiment using BO1-WT or BO1-CSF2KO breast cancer cells in C57BL/6 mice and found 
the same result (Figure 7B). To rule out the effect of genetic differences between CRISPR modified 
cell lines, we established BO1 orthotopic MFP tumors and pharmacologically inhibited GM-CSF 
in the tumor microenvironment using a neutralizing anti-GM-CSF antibody. Compared to isotype 
control antibody treatment, mice receiving anti-GM-CSF antibody had significantly decreased 
tumor growth in WT C57BL/6 mice (Figure 7C). Importantly, pharmacological or genetic 
disruption of tumor-derived GM-CSF did not affect tumor growth in immunocompromised NSG 
mice (Figure 7D-F). These results indicate that tumor-derived GM-CSF promotes tumor growth 
by modulating host immune responses. 
We also tested the role of GM-CSF in a spontaneous tumorigenesis model by crossing MMTV-
PyMT mice with GM-CSF knockout (Csf2-/-) mice to generate Csf2-/- MMTV-PyMT mice and 
evaluated tumor development.  We found that the median time to tumor appearance in WT 
MMTV-PyMT mice was 96 days, while the median time to tumor appearance in Csf2-/- MMTV-
PyMT mice was 130.5 days. We performed immune cell profiling of tumors from these mice 
(harvested at the same tumor size) and found that tumors from Csf2-/- MMTV-PyMT mice had 
decreased ARG1+ CD11b+ myeloid cells and CD4+ T cell infiltration, while CD8+ T cells numbers 
were increased (sFigure 9). These data show that GM-CSF can modulate tumor growth and alter 
tumor immune profiles in a spontaneous breast cancer model. 
It is known that myeloid cells can inhibit T cell function through Arg-1 expression (2, 3, 9, 20), 
and our in vitro data indicated that bone marrow macrophages exposed to breast tumor-secreted 
GM-CSF express Arg-1 and inhibit T cell function (Figure 3). This prompted us to evaluate WT and 
GM-CSF knockout tumor cell growth in myeloid cell-specific Arg-1 knockout mice (Arg1fl/fl LysM-
Cre+/-). Interestingly, as with our studies in immunocompromised NSG mice, we found no 
significant differences in tumor growth in mice lacking Arg-1 in myeloid cells (Figure 7G), 
suggesting that Arg-1 protein expression in myeloid cells is particularly important for GM-CSF-
induced enhancement of tumor growth. 
We next evaluated the immune profile of BO1-WT and BO1-CSF2KO tumors in WT mice. We 
found that in the myeloid cell compartment, total CD45+CD11b+ myeloid cell numbers were 
decreased in BO1-CSF2KO tumors. Among all myeloid cell populations, the number of monocytes, 
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granulocytes, and monocyte-derived dendritic cells was not significantly different between WT 
and GM-CSF knockout BO1 tumors; however, the number of TAMs was decreased in BO1-CSF2KO 
tumors (Figure 7H, sFigure 10). Compared to WT BO1 tumors, TAMs in the BO1-CSF2KO tumors 
were also less polarized towards an M2 phenotype (Figure 7I). Evaluation of the entire population 
of tumor-infiltrating CD45+ cells revealed that the percentage of conventional T cells (Tconv, CD4+ 
Foxp3-), and CD8+ T cells between BO1-WT and BO1-CSF2KO tumors were not significantly 
different. However, BO1-CSF2KO tumors exhibited higher ratios of memory Tconv (CD62L+ CD44+) 
and memory CD8+ T cells (CD3+ CD8+ CD62L+ CD44+), with reduced PD1+ TIM3+ CD8+ T cells 
compared to BO1-WT tumors (Figure 7j, sFigure 11). These data suggest that loss of tumoral GM-
CSF may provide a favorable environment for T cells in breast cancer.  
To evaluate whether Arg-1 and GM-CSF mRNA expression relates to T-cell phenotypes in 
human breast cancer samples, we queried the Gene Expression database of Normal and Tumor 
tissues 2 (GENT2)(36) for correlations between T cell markers and ARG1 or CSF2. Across all breast 
cancer subtypes, we identified a significant positive correlation between ARG1 expression and 
CSF2 expression. In some breast cancer subtypes, especially in luminal B, ARG1 or CSF2 
expression negatively correlated with CD3E expression (sFigure 12). We also evaluated T cell 
subset markers (CD4 and CD8A) and markers that reflect T cell function, including LAG3, HAVCR2, 
PDCD1, and FOXP3. We identified that the expression of the regulatory T cell marker FOXP3, 
significantly correlated with ARG1 and CSF2 expression across all breast cancer subtypes. In some 
breast cancer subtypes, we also observed a correlation between ARG1 or CSF2 expression with 
putative markers of T cell exhaustion, but this signal was not robust across all breast cancer 
subtypes from the current dataset (Supplemental Table 3 and 4). These data suggest that CSF2 
expression correlates with ARG1 expression in human breast cancer tissue, and that the 
expression of CSF2 or ARG1 may reflect an unfavorable environment for T cell function. 
Taken together, tumor-derived GM-CSF modulates tumor-infiltrating host immune cells in a 
myeloid Arg-1 protein expression-dependent manner, resulting in enhanced tumor growth. 
Interruption of tumor cell-derived GM-CSF resulted in decreased TAM infiltration and diminished 
myeloid cell Arg-1 expression, and may enhance the anti-tumor function of infiltrating T cells. 
Disruption of tumor cell-produced GM-CSF enhances the efficacy of immune therapy  
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Because myeloid cells exposed to breast tumor cell-produced GM-CSF suppressed T cell 
function in vitro and enhanced tumor growth in immunocompetent mice, we hypothesized that 
blockade of GM-CSF production from breast tumor cells would increase the efficacy of T cell-
targeted cancer immune therapy.  
We first evaluated the effect of disruption of tumor-derived GM-CSF on the efficacy of 
adoptive T cell transfer therapy. We used CD45.1+ OT-1 TCR-transgenic T cells that are specific 
for chicken ovalbumin (OVA) epitope SIINFEKL (OVA254-267) peptide bound to H-2Kb as the source 
of anti-tumor-specific T cells (37). We genetically modified tumor cell lines to express OVA254-267 
by a retroviral vector (38), and identified them as B16-OVA, BO1-OVA, BO1-WT-OVA, and BO1-
CSF2KO-OVA, respectively. The expression level of SIINFEKL-bound H-2Kb and MHC-I on B16-OVA 
and BO1-OVA were similar (sFigure 13). 
BO1 and mCherry-expressing BO1-OVA cells were cultured together at a 1:1 ratio and exposed 
to in vitro expanded OT-1 T cells. After 16 hours, BO1-OVA cells without OT-1 T cell treatment 
retained their population, while in the treatment group, OT-1 T cells effectively killed OVA254-267 
expressing BO1-OVA cells (Figure 8A). In vivo, adoptively transferred CD45.1+ OT-1 T cells 
effectively inhibited melanoma B16-OVA subcutaneous tumor growth (Figure 8B) but had no 
effect on breast cancer BO1-WT-OVA MFP tumor growth (Figure 8C). In contrast, OT-1 T cells 
attenuated the growth of BO1-CSF2KO-OVA MFP tumors lacking GM-CSF gene expression (Figure 
8D). These results show that in comparison to B16 melanoma cells, BO1 breast cancer cells are 
resistant to adoptive T-cell transfer therapy, and this resistance could be overcome by disrupting 
tumor cell produced GM-CSF. 
As bone metastasis is common and often challenging to treat in patients with breast cancer 
(39), we asked whether disruption of GM-CSF production could enhance adoptive T cell therapy 
in a murine bone metastasis model. We intracardially injected BO1-WT-OVA and BO1-CSF2KO-
OVA tumor cells to establish tumor infiltration into bones and visceral organs in WT C57BL/6 mice 
and injected OT-1 T cells on day 5, monitoring tumor burden by bioluminescence imaging (BLI). 
We found that without OT-1 T cell treatment, there was no significant difference in bone tumor 
burden between WT and GM-CSF knockout tumors; however, with OT-1 T cell treatment, bone 
tumor burden in GM-CSF knockout bone metastases was significantly lower compared to WT 
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(Figure 8E). We further evaluated whether pharmacological blockade of GM-CSF with a 
neutralizing antibody could enhance the efficacy of OT-1 T cell treatment on bone metastases. 
We found that anti-GM-CSF antibody treatment alone did not significantly decrease bone tumor 
burden in our experimental metastasis model; however, when combined with OT-1 T cell 
treatment, neutralization of GM-CSF significantly reduced bone tumor burden (Figure 8F). These 
data suggest that genetic or pharmacologic disruption of tumor cell-derived GM-CSF in preclinical 
models of metastasis can enhance the efficacy of tumor-specific adoptive T cell therapy.  
Next, we tested this hypothesis in a model of immune checkpoint blockade (ICB) therapy. The 
most common ICB targets on T cells are cytotoxic T-lymphocyte antigen 4 (CTLA-4) and 
programmed cell death protein 1 (PD-1) signaling (40). We administered an anti-PD1 antibody 
and anti-CTLA4 antibody as a combined neoadjuvant therapy in an orthotopic spontaneous 
metastatic breast cancer model. We established BO1-WT mammary fat pad tumors in C57BL/6J 
mice and intravenously injected anti-PD1 and anti-CTLA4 antibodies on days 6, 8, and 10, starting 
when T cells and myeloid cells are present within the TME. When the primary tumor size reached 
~1000 mm3, we surgically removed the tumor and monitored mice for evidence of spontaneous 
metastases for 4 weeks by BLI. We found that ICB treatment did not significantly change BO1-WT 
primary tumor growth or the rate of metastasis (Figure 8G-I). However, the same experiment 
performed with BO1-CSF2KO tumors showed that ICB treatment decreased GM-CSF knockout 
primary tumor growth in WT mice. Notably, after tumor resection around 1000mm3, the 
metastasis rate in the control group was around 40%, whereas no metastases were observed in 
the ICB treated group (Figure 8 J-L). These data suggest that disruption of tumor cell-derived GM-
CSF can enhance the efficacy of neoadjuvant ICB treatment in both the primary and metastatic 
settings.  
Overall, our results implicate GM-CSF as a contributor to the development of 
immunosuppression in the TME, and suggest that targeting GM-CSF could enhance the efficacy 








Arg-1 expression and its effect on myeloid cells has been well reported, but not much is known 
about the role and regulation of Arg-1 in breast cancer. Here, we identify GM-CSF produced by 
breast cancer cells as a critical regulator of the immune suppressive TME through effects on Arg-
1 expression in pro-tumor immune suppressive myeloid cells. We show that the effect of GM-
CSF on Arg-1 expression in myeloid cells is triggered by the acidic TME and requires the JAK/STAT3 
and p38 MAPK signaling pathways. Moreover, breast tumor cell-derived GM-CSF promotes 
tumor progression through inhibition of host anti-tumor immunity in preclinical mouse models 
of primary and metastatic tumor growth. We also show that blockade of tumoral GM-CSF 
enhances the efficacy of tumor-specific adoptive T-cell therapy and immune checkpoint blockade. 
Therefore, targeting GM-CSF or downstream pathways of GM-CSF could be an alternate way to 
inhibit myeloid cell Arg-1 expression, reduce immunosuppression in the breast cancer TME, and 
enhance immunotherapy efficacy. 
GM-CSF is largely redundant for steady-state myelopoiesis and virtually undetectable in 
circulation (41), but can be administered systemically to promote neutrophil recovery after 
cytotoxic chemotherapy (42).  Physiologically, GM-CSF exerts most of its effects at the local level 
during immune responses and inflammation (30). GM-CSF can enhance dendritic cell function to 
prime T cells (30, 43) and has been used as an immune adjuvant in cancer vaccines (44). In 
contrast to the anti-tumor effects noted above, several studies have reported that tumor cell-
derived GM-CSF can suppress immune responses, enhancing tumor-infiltrating 
immunosuppressive cells, including TAMs, G-MDSCs, T-regs, and plasmacytoid predendritic cells 
(14, 45-48), although the mechanism is not fully understood. Importantly, in human breast cancer, 
higher levels of GM-CSF expression have been correlated with increased metastasis and reduced 
survival (14-17). 
Here, we show that the pro-tumor and immune suppressive effects of breast tumor-derived 
GM-CSF require the induction of Arg-1 in tumor-infiltrating myeloid cells that are primarily 
recruited from the bone marrow. Genetic disruption of GM-CSF in both TNBC and luminal B 
subtype breast cancer lines (4T1 and PyMT-BO1) substantially decreased the percentage of Arg-
1+ myeloid cells in primary tumor tissue but did not completely inhibit Arg-1 expression, 
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suggesting that host-derived GM-CSF could also contribute to myeloid cell Arg-1 expression in 
the TME.  Multiple cellular sources of GM-CSF have been described, including epithelial cells, 
endothelial cells, fibroblasts, stromal cells, and hematopoietic cells (30, 31, 49), and future 
studies using fresh cancer tissue are aimed at delineating sources of local GM-CSF in the breast 
cancer TME that may contribute to myeloid Arg-1 induction and subsequent immune suppression. 
Arg-1 expression is an established marker of pro-tumor myeloid cells, which have been 
associated with immune suppression and enhanced tumor growth (18-20). Arg-1 metabolizes the 
semi-essential amino acid L-arginine into urea and L-ornithine, and is required for maintaining 
normal cell growth, collagen synthesis, and neuronal development, as well as tissue repair from 
injury (19). In the tumor microenvironment, infiltrating Arg-1 expressing myeloid cells drive 
immunosuppression by depleting extracellular L-arginine, resulting in blockade of T cell receptor 
zeta chain synthesis and inhibition of T cell proliferation (20).  Culture of T cells in media with 
reduced L-arginine levels markedly impairs T cell function (20, 50), while the culture of T cells at 
high levels of L-arginine enhances T cell anti-tumor activity (51). In murine models, treatment of 
tumor-bearing mice with either L-arginine or Arg-1 inhibitors or knockout of Arg-1 in myeloid 
cells decreases tumor growth, reduces metastasis, and relieves myeloid cell-mediated immune 
suppression (29, 52-54). We found that the significant difference in growth between WT and GM-
CSF KO breast tumors was eliminated in Arg1fl/fl LysM-Cre+/- mice, suggesting that the effect of 
breast tumor-derived GM-CSF on the immune suppressive TME specifically requires Arg-1 
expression by myeloid cells.  
Overexpression of Arg-1 mRNA is a poor prognostic factor in many cancer types, including 
neuroblastoma (55), acute myeloid leukemia (AML) (56), ovarian carcinoma (57), and colorectal 
cancer (58). In breast cancer patients, increased arginase activity in both tumor tissue and blood 
was reported, though its prognostic utility has not been established (59-61). We found that in 
both human patient samples and in preclinical cancer models, melanoma and lung tumors had 
significantly lower levels of Arg-1+ myeloid infiltrating cells compared to breast tumors.  
We used a gene expression screen of breast tumor secreted factors to identify GM-CSF as a 
critical factor to promote immune suppressive macrophage polarization. We identified lactic acid 
as a factor that could combine with GM-CSF to induce myeloid Arg-1 levels in a dose-dependent 
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manner. Tumor cell metabolic reprogramming can generate high levels of lactic acid in the TME, 
secreted in the form of lactate and H+ ions by the MCT transporter. Lactate concentration is 
therefore often used as a surrogate measure of metabolic acidosis (2, 28). Neither high levels of 
lactic acid nor GM-CSF alone can induce high-level Arg-1 expression in myeloid cells (Figure 4), 
suggesting that induction of Arg-1 expression in TIMs might be heavily dependent on local, 
overlapping gradients of GM-CSF and lactic acid, in addition to other factors yet to be identified. 
Our screens focused on secreted factors and did not evaluate the impact of direct cell-cell 
interactions, which likely also play a critical role in sculpting immune suppressive tumor 
environments. The significance of this highly local, context-dependent Arg-1 expression by TIMs 
for response to immune therapy in human breast cancer demands further study.  
Myeloid cell Arg-1 expression has been shown to be regulated by IL-4 or IL-13 signaling 
through STAT6 (2, 59), but the STAT6 pathway was dispensable for both breast tumor 
conditioned media and GM-CSF/lactic acid induced Arg-1 expression (Figure 5). A well-known 
signaling pathway downstream of GM-CSF is JAK2/STAT5. Inhibition of JAK1/2 by ruxolitinib 
completely blocked tumoral GM-CSF induced myeloid cell Arg-1 expression; however, the STAT5 
inhibitor CAS 285986-31-4 had no effect. Accordingly, we turned to other pathways known to 
regulate immunosuppressive MDSCs such as STAT3 (62-64), a previously identified target of GM-
CSF signaling in human neutrophils (65, 66). Studies have also showed that both STAT3 and p38 
MAPK signaling can be regulated by JAK2 (67-69). Indeed, we found that blockade of STAT3 or 
p38 MAPK signaling abrogates Arg-1 expression in myeloid cells (Figure 5). Further, we found that 
acid signaling through GPCRs/cAMP pathway was also required for robust Arg-1 induction in 
combination with GM-CSF signaling (Figure 6). Therefore, our data suggest that GM-CSF signals 
through the STAT3 and p38 MAPK pathways within an acidified environment, cooperating with 
signaling through GPPCRs/cAMP to trigger myeloid cell Arg-1 expression. 
The immune profile of GM-CSF knockout tumors in this report exhibited two significant 
differences: decreased percentage of Arg-1+ myeloid cells and decreased total TAM infiltration 
(Figure 7). Either or both phenotypes could contribute to the reduced tumor growth phenotype 
observed in GM-CSF knockout breast tumors. Importantly, GM-CSF disruption restored sensitivity 
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to immune checkpoint blockade and antigen-specific CD8+ T cell therapy. Thus, tumor cell 
produced GM-CSF can modulate TIMs and contribute to an immunosuppressive TME.  
Enhanced anti-tumor T cell activity is critical in current checkpoint immune therapy (1, 70, 71). 
The majority of breast cancer clinical trials are focused on TNBC because this subtype has higher 
numbers of tumor infiltrating lymphocytes (1). However, the overall response rates to checkpoint 
treatment in breast cancer are much lower compared to other cancer types like melanoma or 
lung cancer. Numerous mechanisms of immune suppression have been identified in the breast 
TME, a better understanding of which is clearly required to design rational combination 
treatments for patients. One major potential reason for the failure of such therapeutic 
interventions is that tumor cell metabolism can impact the TME to limit immune responses and 
present barriers to cancer therapy (2, 10, 70, 71). L-arginine is one of the essential nutrients 
required for proper T cell function that can be depleted by Arg-1 expressing myeloid cells in the 
TME (19). There are currently no arginase inhibitors available for clinical use due to in vivo 
stability, bioavailability, and safety issues (59, 72). Here, we found that GM-CSF, a cytokine that 
normally promotes immunity, can induce the immune inhibitory enzyme Arg-1 in acidic 
microenvironments common across a variety of cancers. We described the mechanisms and 
highlighted two signaling pathways, GM-CSF and cAMP, which are critical for myeloid Arg-1 
induction. We also tested several key molecules, JAK1/2, STAT3, p38, adenylyl cyclase, and CREB, 
that can be targeted by inhibitors to block Arg-1 expression in vitro. Several clinical inhibitors 
targeting JAK2, STAT3, and p38 MAPK pathways for cancer treatment are either FDA approved 
or currently in clinical trials. Future studies are underway to evaluate inhibition of Arg-1 
expression using these inhibitors prior to checkpoint therapy in preclinical models.  
Together, our data indicate that targeting of tumor cell produced GM-CSF to alter myeloid cell 
phenotype may alleviate immunosuppression and improve anti-tumor immunity in breast cancer. 
This finding extends our understanding of the immune suppressive tumor microenvironment and 
provides a new strategy for circumventing microenvironment-mediated resistance when 






Materials and Methods: 
 
Mice 
All animal studies were performed according to the guidelines established by the Washington 
University, Institutional Animal Care and Use Committee (WU IACUC). WT mice (JAX 000664), 
LysM-Cre mice (JAX 004781)(73), Arg-1 reporter mice (YARG, JAX 015857)(24), Arg1fl/fl mice (JAX 
008817)(74), GM-CSF KO (Csf2-/-) mice (JAX 026812)(75), OT-1 mice (JAX 003831)(37), CD45.1 
mice (JAX 002014), Stat6-/- mice (JAX 005977)(76) and MMTV-PyMT mice (JAX 022974)(77) are 
all C57BL/6J background and from the Jackson Laboratory. BALB/c mice (JAX 000651) and NOD 
SCID gamma (NSG) mice (JAX 005557) are also from the Jackson Laboratory. Arg1fl/fl mice were 
crossed with LysM-Cre mice to obtain Arg-1 myeloid cell conditional knockout mice (Arg1fl/fl 
LysM-Cre+/-). YARG mice were crossed with Stat6-/- mice to obtain Stat6-/- YARG mice. OT-1 mice 
were crossed with CD45.1 mice to obtain OT-1-CD45.1 mice. For in vivo experiments, 8 to 12-
week-old mice were used. Mice used for in vitro experiments were 6 to 12 weeks old. All mice 
are housed under pathogen-free conditions according to the guidelines of the WU IACUC.  
Cell lines and constructs 
The BALB/c background 4T1-FL-GFP murine mammary tumor cell line was originally from Dr. 
David Piwnica-Worms (The University of Texas, Houston, TX) as previously described (78). The 
C57BL/6J background PyMT-BO1-GFP-Luc murine mammary tumor cell line was previously 
reported (22). Both murine breast tumor cell lines had been previously modified to express firefly 
luciferase and green fluorescent protein. The B16F10-Luc murine melanoma and LLC-Luc murine 
lung cancer cell lines were provided by Dr. Hodivala-Dilke (UK) (79). Non-labeled B16 and LLC cell 
lines are from ATCC. Gene knockout cell lines were made using the lentiCRISPR v2 vector system 
(Addgene 52961), as described (80). All gRNA sequences used for CRISPR knockout experiments 
are listed in Supplementary Table 1. Virus was packaged using 293T cells and helper plasmids 
pCMV-DR8.2 and pCMV-VSVG. Tumor cell lines were transduced with viral supernatant for 12 h 
at 37°C in 6-well tissue culture plates and selected with 5-10 ug/mL puromycin for 3 days. All 
CRISPR knockout cell lines were validated by ELISA or western blot. 
GM-CSF overexpressing B16 and LLC cell lines were established by transfection of plasmid DNA 
of murine Csf2 vector pCR3.1-mGM-CSF (Addgene 74465)(81) using lipofectamine 3000 (Thermo 
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Fisher Scientific) and selected with 1mg/mL G418 for one week. GM-CSF expression from 
established cell lines (B16-GM and LLC-GM) were confirmed by ELISA. 
OVA257-264 expressing cell lines were established as described (38). Briefly, HEK293T Phoenix-
Ampho cells were transfected with PresentER-SIINFEKL (mCherry) vector (Addgene 102945). 
After 24 h, cell culture viral supernatant was harvested every 12 h. Tumor cell lines were 
transduced with viral supernatant for 12 h at 37 degrees in 6-well tissue culture plates. All cell 
lines were selected with puromycin and purified by FACS sorting according to mCherry expression. 
All cell lines were maintained in Dulbecco’s Modified Eagle's Medium (DMEM) (Gibco) 
supplemented with 10% fetal bovine serum (Sigma) and penicillin/streptomycin (Gibco). All cell 
lines tested negative for mycoplasma. 
Mice tumor models 
4T1 cells were implanted into BALB/C mice, and PyMT-BO1 cells were implanted into C57BL/6 
mice. NSG mice received cell lines from both backgrounds. In vivo orthotopic breast tumor 
models were established by injection of 1x105 tumor cells, mixed with BD matrigel (BD 
biosciences) or with PBS in a total of 40 µL, into the fourth mammary fat pad (MFP) tissue of 8-
week-old female mice.  
For subcutaneous injections, 1x106 tumor cells in 200 µL PBS were injected into the flank of 
mice. Tumor growth was monitored and measured with digital calipers. 
Breast tumor bone metastasis models were established by intracardiac injection with 1x105 
tumor cells in 50 µL PBS into 6-week-old mice, as previously described (82). Bioluminescence 
imaging was used to quantify tumor growth after injection. For antibody treatment, mice were 
given anti-PD1 and anti-CTLA4 antibodies (2.5mg/kg, Bioxcell) by intravenous injection at the 
indicated time points. For localized anti-GM-CSF antibody treatment, 1x105 BO1-GFP-Luc breast 
tumor cells were mixed with matrigel plus either isotype antibody (Control) or anti-GM-CSF 
antibody before injection into MFP tissue of 8 weeks old female C57BL/6J mice. In metastasis 
models, anti-GM-CSF antibody (2.5mg/kg, Bioxcell) was administered by intravenous injection at 
the indicated time points. 
For adoptive T cell treatment experiments, OT-1 T cells expanded in vitro before i.v. injection. 
Briefly, spleen cells from OT-1-CD45.1 mice were harvested and stimulated with 0.5g/mL OVA 
peptide and 10 ng/mL IL-2 in T-75 flask, media were refreshed every day with IL-2 for three days. 
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At day 4, T cells were harvested and CD8+ T cells were purified with MACS CD8 magnetic beads 
and counted, resuspended in PBS before injection. 
In vivo bioluminescence imaging 
For bioluminescence imaging of live animals, as previously described (82), mice were injected 
intraperitoneally with 150 µg/g D-luciferin (Biosynth, Naperville, IL) in PBS, anesthetized with 2.5% 
isoflurane, and imaged with a charge-coupled device (CCD) camera-based bioluminescence 
imaging system (IVIS 100; Caliper, Hopkinton, MA; exposure time 1-60 seconds, binning 8, field 
of view 12, f/stop 1, open filter, anterior side).  Signal was displayed as photons/sec/cm2/sr. 
Regions of interest (ROI) were defined manually around the legs using Living Image and IgorPro 
Software (Version 2.50).   
Bone marrow macrophage culture and treatment 
To generate primary bone marrow macrophages (BMMs), whole bone marrow was extracted 
from the femurs and tibias of mice, plated in Petri dishes in DMEM containing 10% fetal bovine 
serum and 50ng/mL M-CSF, and cultured in a 37°C, 5% CO2 incubator. Day 3 cultured BMMs were 
plated at 5x105 per well in 6-well cell culture plates and treated with GM-CSF (2ng/mL), IL-4 
(2ng/mL), or lactic acid (0-20 mM) for 24 h before analysis. Pathway agonist or inhibitors are 
listed: JAK1/2 inhibitor (Ruxolitinib, Millipore Sigma), STAT3 inhibitor (C188-9, Millipore Sigma), 
STAT5 Inhibitor (CAS 285986-31-4, Millipore Sigma), MEK inhibitor (Trametinib, Cell Signaling 
Technology), ERK inhibitor (Ulixertinib, Chemie Tek), P38 MAPK inhibitor (SB203580, AdipoGen), 
Pertussis toxin (Millipore Sigma), Forskolin (Millipore Sigma), Adenylyl cyclase inhibitor (MDL-12, 
Millipore Sigma), cAMP-response element-binding protein (CREB) inhibitor (KG-501, Millipore 
Sigma). All inhibitors were used as pre-treatment 1-2 h before given cytokines or tumor 
conditioned media. Tumor cell-conditioned media were collected from 24 h cultured tumor cells 
with a cell density of 5X105 cells per 1mL DMEM media. Tumor conditioned media were 1:1 or 
1:2 diluted with fresh media before BMMs treatment. After 24 h or indicated treatment time, 
cells were detached with DPBS plus 5mM EDTA and directly used for FACS analysis, lysis for 
western blot, or harvest for qPCR. 
Microarray analysis 
Microarray was performed with the Genome Technology Access Center at Washington 
University School of Medicine. The microarray data in this article are available on the GEO 
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database with accession number GSE75882 (22). PyMT-BO1-GFP-Luc cells and CD206hi TAMs 
were FACS sorted from day 10 MFP tumor tissue. RNA was isolated from tumor cells and CD206hi 
TAMs using a Nucleospin RNA II Kit (Clonetech). Data were analyzed as described (22). 
Lactate and media pH measurements 
Lactate concentration from cell culture conditioned media was measured with L-Lactate Assay 
Kit I (120001, Eton Bioscience) according to the manufacturer’s protocol. Cell culture conditioned 
media pH was measured by a digital pH meter. 
Flow cytometry 
Tumor tissues were prepared in single-cell suspension for FACS analysis. Briefly, tumor tissue 
was manually minced using a scalpel, followed by enzymatic digestion with 1 mg/mL collagenase 
A (Roche) and DNase I (Sigma-Aldrich) for 30 minutes at 37°C with constant stirring. Cells were 
filtered through 100 µm nylon strainers (Fisher Scientific), then washed twice in 2% FBS PBS. After 
counting, 1x106 total cells were placed in 200 µL buffer (PBS plus 2% FBS) and incubated for 20 
minutes with fluorophore-conjugated anti-mouse antibodies using the manufacturers' 
recommended concentrations. All antibodies used are listed in Supplementary Table 2. Data 
acquisition was performed on the LSR-II or X20 system (BD Biosciences), and FlowJo software 
version 10 (Tree Star) was used for analysis. 
Statistics 
GraphPad Prism Version 7 (GraphPad Software Inc.) was used for statistical analyses. 
Differences between groups were evaluated by unpaired 2-tailed Student’s t test or 2-way 
ANOVA for repeated measures. Data are presented as mean ± SEM. P values of less than 0.05 
were considered statistically significant. 
Study approval 
Animal work was performed according to the policies of the WU IACUC at Washington 
University School of Medicine in St. Louis. Mice were analyzed under approved protocols and 
were provided appropriate care while undergoing research that complied with the standards in 
the Guide for the Use and Care of Laboratory Animals (National Academies Press, 2011) and the 
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Figure 1. Immunosuppressive Arg-1 expressing myeloid cells accumulated in the breast tumor 
microenvironment 
(A) 1x105 PyMT-BO1 breast tumor cells were injected into the MFP tissue of C57BL/6J female 
mice and tumor growth was measured by digital caliper.  (B) Single-cell suspensions from whole 
tumor tissue were analyzed by FACS at day 6, 10 and 15 of tumor growth. The tumor-infiltrating 
myeloid cell and T cell populations are shown. Tumor-associated macrophages (TAMs) markers 
are CD45+, CD11b+, Ly6C-, Ly6G-, and F4/80+. M1 TAMs are MHCII+, and M2 TAMs are CD206+. (C) 
Tumor weights from PyMT-BO1 orthotopic tumors in the YARG mice. (D) Percentage of Arg-1 
expressing myeloid cells in CD45+ CD11b+ tumor-infiltrating myeloid cells (TIMs). (E) Percentage 
of TIM subpopulations in total CD45+ CD11b+ myeloid cells from day 10 tumors. The Arg-1- cells 
(white) and Arg-1+ cells (blue) are labeled in each subpopulation. (F) Arg-1 expressing myeloid 
cells in CCR2hi and CCR2low CD45+ CD11b+ myeloid cells. (G) Arg-1 expressing CD45+ CD11b+ 
myeloid cells in PyMT-BO1 breast cancer MFP tumor tissue, B16F10 melanoma, and LLC lung 
cancer subcutaneous tumor tissue. (H) Immunofluorescent staining of paraffin embedded BO1 

































Figure 2. Arg-1 expressing myeloid cells accumulated in human breast cancer tissue 
Lung cancer (n=10), melanoma (n=10), and breast cancer (n=60) tissue microarrays (TMAs) were 
used for immunofluorescent staining. (A) CD68+ myeloid cell number per mm2 tissue area, and 
(B) Percentage of ARG1+ cells in total CD68+ cells from lung cancer, melanoma, and breast cancer 
tissues. (C) CD68+ myeloid cell number per mm2 tissue area, and (D) Percentage of ARG1+ cells in 
total CD68+ cells from breast cancer subtypes. (E) ARG1+ CD68+ myeloid cell number per mm2 
tissue area from breast cancer based on cancer stage. (F) Representative immunofluorescent 
staining pictures of paraffin-embedded human cancer tissue. Bar=500 m for whole tissue 
pictures, Bar=100 m for enlarged pictures. Data are shown as mean ± SEM, using a two-tailed, 





































Figure 3. Tumor cell produced GM-CSF is necessary to induce myeloid cell Arg-1 expression 
(A) Arg1 mRNA expression from BMMs treated with LLC, B16F10, PyMT-BO1, and 4T1 tumor cell-
conditioned media (CM) (n=2 or 3). (B) CFSE labeled whole spleen cells stimulated with plate-
banded anti-CD3E antibody and soluble anti-CD28 antibody, co-cultured with 1:1 diluted CM 
from PyMT-BO1 or FACS sorted Arg-1+ or Arg-1- BMMs pre-treated with PyMT-BO1 CM. T cell 
proliferation was measured from quantification of CFSE dilution in gated CD4+ T cells by FACS 
(n=3). (C) Microarray analysis of gene expression from breast tumor cells and CD206+ TAMs 
sorted by FACS from the same tumor tissue. (D) Arg1 mRNA expression in BMMs treated with 
tumor cell CM from PyMT-BO1 or CRISPR/Cas9 mediated gene knockout PyMT-BO1 tumor cells 
(n=2). (E) Western blot of ARG1 from tumor cell CM treated BMMs. (F) Quantification of GM-CSF 
level from tumor cell CM by ELISA (n= 2-4). (G, H) Arg1 mRNA expression from BMMs treated 
with tumor cell CM that included anti-CSF2 antibody or CSF2 (n=2). (I) Arg-1 expression quantified 
as EYFP expression by FACS from YARG BMMs treated as indicated. (J) 1x105 BO1-WT (vector 
control) or BO1-CSF2KO breast tumor cells injected into MFP tissue of 8-week-old female YARG 
mice. At day 10, single-cell suspensions from whole tumor tissue were analyzed by FACS. Arg-1 
expression in TIMs is quantified as EYFP expression. In E and I, data are representative of three 
independent experiments. Data are shown as mean ± SEM, *p<0.05, **p<0.01, ***p≤0.001, using 






























Figure 4. GM-CSF and lactic acid synergistically induce myeloid cell arginase 1 expression 
(A) Arg1 mRNA expression from BMMs treated with recombinant GM-CSF or PyMT-BO1 tumor 
cell CM (n=2 or 3). (B) ARG1+ cells quantified by FACS from YARG BMMs treated with recombinant 
GM-CSF or PyMT-BO1 tumor cell CM. (C) Arg1 mRNA expression from BMMs treated with tumor 
cell CM plus recombinant GM-CSF (n=2 or 3). (D) Quantification of lactate from tumor cell CM. 
(E) Arg1 mRNA expression from BMMs treated with recombinant GM-CSF and lactic acid. (F) 
ARG1+ cells quantified by FACS. (G) ARG1 expression in BMMs was detected by western blot after 
GM-CSF and lactic acid treatment. (H) Lactate production from tumor cell-conditioned media 
(n=3). (I) Tumor conditioned media pH measurement (n=3). (J) Arg1 mRNA expression from 
BMMs (n=3). (K) ARG1+ cells quantified by FACS. (L) YARG BMMs treated with GM-CSF, media pH 
adjusted with hydrochloric acid (HCL). (M) BO1 tumor CM pre-mixed with NaHCO3 as indicated 
concentration before added to YARG BMMs. In B, F, G, and K-M, data are representative of three 
independent experiments. Data are shown as mean ± SEM, *p<0.05, **p<0.01, ***p≤0.001, using 


































Figure 5. GM-CSF signaling regulates myeloid cell Arg-1 expression through non-canonical 
pathways 
 (A) Experiment scheme. (B) WT or Stat6-/- YARG BMMs treated with recombinant IL-4 or PyMT-
BO1 tumor cell CM for 24 h, ARG1+ cells quantified by FACS. (C) Arg1 mRNA expression in WT and 
Stat6-/- BMMs treated with IL-4 or PyMT-BO1 tumor cell CM (n=2 or 3). (D) Experiment scheme. 
(E, F) 1x105 PyMT-BO1 tumor cells injected into MFP tissue of WT or Stat6-/- YARG mice. After 
tumor measures 500 mm3, ARG1+ cells are quantified by FACS from whole tumor tissue single-
cell suspensions (n=6). (G) Working model of GM-CSF receptor signaling. (H, I) ARG1+ cells 
quantified by FACS in YARG BMMs pre-treated with DMSO, JAK1/2 inhibitor Ruxolitinib, STAT3 
inhibitor C188-9, STAT5 inhibitor CAS 285986-31-4, ERK1/2 inhibitor Ulixertinib, p38 inhibitor 
SB203580, and MEK inhibitor Trametinib for 1 h, followed by treatment with BO1 tumor cell CM 
for 24 h (n=2-5). Data are shown as mean ± SEM, *p<0.05, **p<0.01, ***p≤0.001, using a two-



































Figure 6. Tumor cell-derived GM-CSF induced myeloid cell Arg-1 expression require cAMP 
signaling 
(A) Working model that G-protein coupled receptors (GPCRs) associated subunit Gs and Gi 
regulate cAMP level. (B) 5x105 BMMs from Arg-1-YFP mice were seeded in 6-well plate overnight. 
BMMs pre-treated with pertussis toxin (PTX) for 2 h before adding tumor cell CM. (C, D) Forskolin 
(Fors) was added to the BMMs at the same time with indicated treatments. (E-F) Inhibitors added 
1 h before CM or 2ng/mL GM-CSF plus 20 mM lactic acid (CSF2/LA) treatment. All BMMs were 
treated for 24 h by CM or CSF2/LA before FACS analysis. In B-F, data are representative of three 
independent experiments.  (G) A working model that GM-CSF (CSF2) and cAMP signaling combine 






































Figure 7. Breast tumor-derived GM-CSF promotes tumor growth through the modulation of 
host immune cells 
(A) 1x105 4T1-WT (vector control) or 4T1-CSF2 knockout breast tumor cells injected into MFP 
tissue of 8-week-old female BALB/C mice (n=7 or 8). (B) 1x105 BO1-WT (vector control) or BO1-
CSF2 knockout breast tumor cells injected into MFP tissue of 8-week-old female C57BL/6J mice 
(n=9 or 11). (C) 1x105 BO1-GFP-Luc breast tumor cells mixed with matrigel plus isotype antibody 
(Control) or anti-CSF2 antibody before injected into MFP tissue of 8-week-old female C57BL/6J 
mice (n=9). (D-F) The same experiments in A-C were performed in NSG mice (n=4-8). (G) The 
same experiment as (B) was performed in Arg1fl/fl LySM-Cre+/- mice (n=8 or 10). For all the above 
experiments, tumor growth is measured by digital calipers. At day 24, MFP tumors were dissected 
and weighed. (H-J) Single-cell suspensions from day 10 BO1-WT or BO1-CSF2KO whole tumor 
tissue (C57BL/6J mice) were analyzed by FACS. Populations of the tumor-infiltrating myeloid cells 
(TIMs) and T cells are shown (n=7). Statistical comparisons by 2-way ANOVA for repeated 
measures or a two-tailed, unpaired t-test with Welch’s correction between groups for column 

































Figure 8. Disruption of tumor cell produced GM-CSF enhances breast cancer immune therapy 
(A) BO1 cells (GFP+) were co-cultured with BO1-OVA cells (GFP+ mCherry+) at 1:1 ratio, then OT-
1 T cells were added for 16 h and analyzed by FACS.  (B) 1x106 B16F10-OVA cells were s.c. injected 
in the C57BL/6j mice. At day 5, one group treated with 5x106 in vitro expanded OT-1 T cells via 
i.v. injection Tumor size was measured by digital calipers. (C, D) 1x105 PyMT-BO1-WT-OVA or 
PyMT-BO1-CSF2KO-OVA breast tumor cells were inoculated with PBS in MFP tissue. At day 7, 
5x106 OT-1 T cells were i.v. injected. (E) 1x105 PyMT-BO1-WT-OVA or PyMT-BO1-CSF2KO-OVA 
breast tumor cells were injected intracardiac into 6-week-old female C57BL/6 mice (n= 5 or 6). 
At day 5, 5x106 OT-1 T cells were injected via i.v. Representative pictures of BLI on day 12 were 
shown. (F) 1x105 PyMT-BO1-OVA breast tumor cells were injected intracardiac into 6-week-old 
female C57BL/6 mice (n= 5 or 6). At day 5, 7, and 11, anti-CSF2 antibody was intravenously 
injected in antibody treatment groups. At day 5, 5x106 OT-1 T cells injected via i.v. Representative 
pictures of BLI on day 12 were shown. (G) 1x105 PyMT-BO1-V2 breast tumor cells were injected 
into MFP tissue of 8-week-old female C57BL/6 mice. At day 6, 8, and 10, anti-PD1 and anti-CTLA4 
antibodies (2.5mg/kg) were injected by i.v. (H) Primary tumor mastectomies were performed 
when tumor size reached 1200 mm3. The primary tumor weight after mastectomy is shown. (I) 
After 4 weeks of primary tumor mastectomy, distant metastasis was detected by BLI. The ratio 
of metastatic events and representative pictures of BLI are shown. (J-L) The same experiments 
were performed using PyMT-BO1-CSF2KO breast tumor cells. Statistical comparisons by 2-way 
ANOVA. Data are shown as mean ± SEM, *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001. 
 
 
 
 
 
 
